| Today’s Big NewsMar 13, 2024 |
| By Kevin Dunleavy It didn’t take long for Johnson & Johnson CEO Joaquin Duato to catch up to his predecessor. After paying Duato $13.1 million in his first year as CEO, the pharma giant more than doubled his compensation to $28.4 million last year, according to a regulatory filing. |
|
|
|
By Max Bayer In 2022, the highest-paid R&D executive made $12.2 million. John Reed, M.D., Ph.D., of Johnson & Johnson is telling the rest of the field to hold his beaker. |
By Conor Hale A trio of cardiovascular companies bolstered their transcatheter aortic valve replacement programs at the Cardiovascular Research Technologies conference in Washington, D.C. |
By Andrea Park The pharma's new campaign encourages people to talk about their family health history in hopes of identifying hereditary diseases they might be carrying as early as possible. |
|
Wednesday, March 27, 2024 | 10am ET / 7am PTThere can be numerous challenges encountered during biopharmaceutical process development. Join usfor an important look at formulation development specifically. Featuring real-world examples, this insightful discussion will explore key challenges, as well as the latest techniques and solutions for effectively overcoming current obstacles. Register now. 
|
|
By Zoey Becker The Swiss skincare company set its price range for a public offering after years of delays, with its listing now expected on March 22. The IPO could be one of Europe's largest this year. |
By Annalee Armstrong With the FDA due to announce the approval of the first drug for metabolic dysfunction-associated steatohepatitis (MASH), Ionis Pharmaceuticals is raising its hand to showcase a phase 2 asset that has improved symptoms of the liver disease. |
By Conor Hale Incorporated as a separate charitable organization, the GE HealthCare Foundation will also work to address an international shortage of primary care clinicians, nurses and midwife professionals. |
By Gabrielle Masson Sanofi will be closing the doors to a U.K. research facility, a move that will impact around 90 people, a spokesperson told Fierce Biotech. |
By Angus Liu Ahead of an important advisory committee meeting, the FDA has raised concerns about early trial deaths for multiple myeloma cell therapies. At the meeting, experts will discuss applications that aim to move the CAR-T therapies Carvykti and Abecma into earlier lines of treatment. |
By Max Bayer Mindstate Design Labs' lead AI-derived psychedelic is headed for the clinic after the biotech filed an IND with the FDA. The former Y Combinator company is still chugging off an $11.5 million seed round but is now considering next financing plans. |
Fierce podcasts Don’t miss an episode |
| In this week's episode of "The Top Line," join Conor Hale, Senior Editor of Fierce Medtech, and Andrea Park, Deputy Editor of Fierce Life Sciences, as they share the highlights of this year's Fierce Medtech Fierce 15. |
|
|---|
|
|
|
Monday, April 22, 2024 | 10am ET / 7am PTExplore cutting-edge NASH research with a novel NAFLD/NASH animal model mirroring patient experiences. Witness Resmetirom's impact on fat accumulation using human cell-based in vitro models. Expect clinical relevance, quick insights in 12-16 weeks, and cost savings. Register now! 
|
|
Whitepaper Explore the nuanced approaches necessary for successful pediatric drug development. Sponsored by: PPD |
Whitepaper This paper assesses the current state of the broad CNS market, reviewing key expectations for 2024. It addresses Alzheimer’s disease, biomarkers, and advances in psychiatry in detail. It also provides a high-level look at the pain market and the evolving regulatory environment. Presented by Blue Matter, strategic consultants in the life sciences |
| |
|
